Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
- 277 Downloads
Although people who use drugs (PWUD) are one of the key risk populations who could benefit from the use of pre-exposure prophylaxis (PrEP), to date, little attention has been given to incorporating PrEP into HIV prevention approaches targeting this underserved group. This study investigated the acceptability of PrEP based on a number of known PrEP attributes among high-risk PWUD in a drug treatment setting. A total of 400 HIV-negative PWUD, who reported drug- and/or sex-related risk behaviors were recruited from a methadone clinic to complete a stated preference (full-profile conjoint) survey. Participants ranked the eight hypothetical PrEP program scenarios with varied combinations of six attributes related to PrEP (cost, dosing, efficacy, side-effects, treatment setting, and frequency of HIV testing). SPSS conjoint procedure was used to estimate the relative importance of each attribute and preferences across eight possible PrEP delivery programs. PrEP acceptability ranged from 30.6 to 86.3% with a mean acceptability of 56.2% across the eight hypothetical PrEP program scenarios. The PrEP program scenario with the highest acceptability had the following attribute levels: insurance covered, daily dosing, 95% effective, no side-effects, treatment at HIV clinic, and HIV testing needed every 6 months. The cost associated with PrEP was the most important attribute (relative importance score: RIS = 38.8), followed by efficacy (RIS = 20.5) and side effects (RIS = 11.9); other attributes had no significant effect. Our findings reported a high acceptability of PrEP in response to different PrEP program scenarios with different attribute profiles. As the result of having this information, researchers and policymakers will be better equipped for evidence informed targeting and dissemination efforts to optimize PrEP uptake among this underserved population.
KeywordsHIV prevention Pre-exposure prophylaxis (PrEP) Conjoint analysis Patient preferences Implementation science People who use drugs (PWUD)
Source of Funding
This work was supported by grants from the National Institute on Drug Abuse for research (R01 DA025943 to FLA) and for career development (K24 DA017072 to FLA; K02 DA033139 to MMC, K24 AR060231 to LF).
Compliance with Ethical Standards
Conflicts of interest
The authors have no conflicts of interest to disclose.
The study protocol was approved by the Investigational Review Board (IRB) at the University of Connecticut and received board approval from APT Foundation Inc. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 5.Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90.CrossRefGoogle Scholar
- 6.CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Washington, DC: Department of Health and Human Services USA—Centers for Disease Control and Prevention; 2014.Google Scholar
- 7.WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015.Google Scholar
- 8.The White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: Updated to 2020. In. Washington D.C.: The White House Office of National AIDS Policy; 2015.Google Scholar
- 9.McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Mannheimer S, Hirsch-Moverman Y, Loquere A, Franks J, Hughes J, Ou S-S, et al. HPTN 067/ADAPT study: a comparison of daily and intermittent pre-exposure prophylaxis dosing for HIV prevention in men who have sex with men and transgender women in New York city. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY: INT AIDS SOCIETY AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND; 2015.Google Scholar
- 12.Holtz TH, Chitwarakorn A, Curlin ME, Hughes J, Amico KR, Hendrix C, et al. (2015) HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand. Journal of the International Aids Society: INT AIDS Society Avenue De France 23, Geneva, 1202, Switzerland; 2015.Google Scholar
- 13.Bekker L-G, Grant R, Hughes J, Roux S, Amico R, Hendrix C. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2015. pp. 23-26.Google Scholar
- 20.Liu A, Colfax G, Cohen S, Bacon O, Kolber M, Amico K, et al. The spectrum of engagement in HIV prevention: proposal for a PrEP cascade. In: 7th International Conference on HIV Treatment and Prevention Adherence Florida: Miami Beach; 2012.Google Scholar
- 21.Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, Sayles JN, et al. Acceptability of Pre-Exposure Prophylaxis (PrEP) as an HIV prevention strategy: barriers and facilitators to PrEP uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–62.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Ward J, Darke S, Hall W. The HIV risk-taking behaviour scale (HRBS) manual. Randwick: University of New South Wales Sydney, National Drug and Alcohol Research Centre; 1990.Google Scholar
- 29.Foxall GR, Menon RV, Sigurdsson V. Conjoint analysis for social media marketing experimentation: choice, utility estimates and preference ranking. Manag Decis Econ. 2016;37(4–5):345–59.Google Scholar
- 38.Corp IBM. IBM SPSS statistics for windows, version 23. Armonk: IBM Corp.; 2015.Google Scholar
- 40.Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:CD004145.Google Scholar
- 43.Goedel WC, Halkitis PN, Greene RE, Duncan DT. Correlates of awareness of and willingness to use pre-exposure prophylaxis (PrEP) in gay, bisexual, and other men who have sex with men who use geosocial-networking smartphone applications in New York City. AIDS Behav. 2016;20(7):1435–42.CrossRefPubMedGoogle Scholar
- 47.Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23(9):1136–45.CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Gersh JK, Fiorillo SP, Burghardt L, Nichol AC, Thrun M, Campbell TB. Attitudes and barriers towards pre-exposure prophylaxis (Prep) among high-risk HIV-seronegative men who have sex with men. J AIDS Clin Res. 2014;5(335):2.Google Scholar
- 53.Shrestha R, Huedo-Medina T, Altice F, Krishnan A, Copenhaver M. Examining the acceptability of mHealth technology in HIV prevention among high-risk drug users in treatment. AIDS Behav. 2016.Google Scholar
- 54.Shrestha R, Huedo-Medina T, Copenhaver M. Sex-related differences in self-reported neurocognitive impairment among high-risk cocaine users in methadone maintenance treatment program. Subst Abus. 2015;9:17–24.Google Scholar
- 64.Markowitz M, Frank I, Grant R, Mayer K, Margolis D, Hudson K, et al. ÉCLAIR: phase 2A safety and PK study of cabotegravir LA in HIV-uninfected men. In: Conference on Retroviruses and Opportunistic Infections; 2016. pp. 22–25.Google Scholar
- 65.Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14(1):231.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.CrossRefPubMedPubMedCentralGoogle Scholar
- 73.Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse. 2012;38(3):206–12.CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.CrossRefPubMedPubMedCentralGoogle Scholar
- 83.Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L, et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017;173:107–16.CrossRefPubMedGoogle Scholar